Kuros Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Kuros Biosciences has a total shareholder equity of CHF60.2M and total debt of CHF0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CHF77.3M and CHF17.1M respectively.
Key information
0%
Debt to equity ratio
CHF 0
Debt
| Interest coverage ratio | n/a |
| Cash | CHF 14.28m |
| Equity | CHF 60.18m |
| Total liabilities | CHF 17.13m |
| Total assets | CHF 77.30m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0RHR's short term assets (CHF33.2M) exceed its short term liabilities (CHF12.2M).
Long Term Liabilities: 0RHR's short term assets (CHF33.2M) exceed its long term liabilities (CHF5.0M).
Debt to Equity History and Analysis
Debt Level: 0RHR is debt free.
Reducing Debt: 0RHR has no debt compared to 5 years ago when its debt to equity ratio was 0.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0RHR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 0RHR has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 13.1% each year.